Apellis (APLS) Form 144: Insider Sale of 189 Shares ($4,572)

Apellis Pharmaceuticals, Inc. (APLS) Form 144 notice reports a proposed sale of 189 shares of common stock held at Fidelity Brokerage Services with an aggregate market value of $4,572.29.

Rhea-AI Filing Summary

Apellis Pharmaceuticals, Inc. (APLS) Form 144 notice reports a proposed sale of 189 shares of common stock held at Fidelity Brokerage Services with an aggregate market value of $4,572.29. The shares, part of restricted stock that vested on 09/12/2025, were acquired from the issuer as compensation and the filer plans an approximate sale date of 09/15/2025 on NASDAQ. The filing also discloses that the same account sold 548 shares on 09/02/2025 for gross proceeds of $15,386.20. These amounts are small relative to the reported 126,289,910 shares outstanding, and the filer represents no undisclosed material adverse information.

Positive

• Full Rule 144 disclosure provided including acquisition date, nature of acquisition, broker, planned sale date, and prior sales
• Insider attestation present stating no undisclosed material adverse information

Negative

• None.

Insights

Securities Analyst

TL;DR: Routine insider sale from vested restricted stock; immaterial to overall share base.

The filing indicates a small, scheduled sale of vested restricted common stock: 189 shares valued at $4,572.29, with a recent prior sale of 548 shares for $15,386.20. Given the issuer's stated 126,289,910 shares outstanding, these transactions represent a negligible percentage of the float and are typical of insiders monetizing small vested awards for liquidity. The filing includes the standard attestation about absence of undisclosed material information.

Corporate Governance Expert

TL;DR: Disclosure aligns with Rule 144 requirements; no governance red flags from this notice alone.

This Form 144 provides required details: acquisition date (09/12/2025), nature (restricted stock vesting), planned sale date (09/15/2025), broker, and historical sales in the past three months. The signatures/attestations included are standard. There is no indication in the document of irregular trading plans or undisclosed material information, and the transaction sizes are immaterial versus total shares outstanding.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Apellis (APLS) Form 144 report?

The notice reports a proposed sale of 189 shares of common stock (aggregate market value $4,572.29) acquired via restricted stock vesting on 09/12/2025.

When are the shares expected to be sold?

The filing lists an approximate sale date of 09/15/2025 on NASDAQ.

How many shares has the filer sold recently?

The filer sold 548 shares on 09/02/2025 for gross proceeds of $15,386.20.

Who is the broker handling the proposed sale?

Fidelity Brokerage Services LLC, 900 Salem Street, Smithfield RI 02917

How material is this sale relative to Apellis outstanding shares?

Materiality is low: 189 shares versus 126,289,910 shares outstanding as reported in the filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 09/15/2025 - 03:20 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001836430
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Apellis Pharmaceuticals, Inc.
SEC File Number	001-38276
Address of Issuer	100 FIFTH AVENUE WALTHAM MASSACHUSETTS 02451
Phone	617-977-5700
Name of Person for Whose Account the Securities are To Be Sold	Chopas James George
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	189	4572.29	126289910	09/15/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	09/12/2025	Restricted Stock Vesting	Issuer			189	09/12/2025	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
James G. Chopas 100 Fifth Avenue Waltham MA 02451	Common	09/02/2025	548	15386.20

144: Remarks and Signature

Remarks	Sale includes an amount necessary to cover a tax obligation resulting from the settlement of a vested equity award distribution.
Date of Notice	09/15/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/Wade Moss, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for James G. Chopas
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)